Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application

作者：Mandai Masaki^*; Hamanishi Junzo; Abiko Kaoru; Matsumura Noriomi; Baba Tsukasa; Konishi Ikuo

来源：International Journal of Clinical Oncology, 2016, 21(3): 456-461.

DOI：10.1007/s10147-016-0968-y

• Ovarian cancer
• Immunotherapy
• PD-L1/PD-1
• Immune checkpoint inhibitor

Tumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and novel treatment modalities, including immune therapy, are needed. However, a basic understanding of tumor immunity associated with the PD-L1/PD-1 signal has only recently emerged. In this review, we first discuss the importance of local tumor immunity, which affects the clinical outcome of ovarian cancer. We subsequently provide an overview of the basic findings regarding how the PD-L1/PD-1 signal influences local tumor immunity in ovarian cancer. Finally, we discuss what is needed to apply immune therapy in future clinical medicine.

• 出版日期2016-6